Mill Capital Management LLC Purchases New Position in Boston Scientific Corporation $BSX

Mill Capital Management LLC purchased a new stake in Boston Scientific Corporation (NYSE:BSX) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 230,815 shares of the medical equipment provider’s stock, valued at approximately $9,851,000.

Several other hedge funds have also bought and sold shares of BSX. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific during the fourth quarter worth $26,000. Sfam LLC purchased a new stake in Boston Scientific during the fourth quarter worth $29,000. Finally, Cresta Advisors Ltd. acquired a new stake in Boston Scientific during the fourth quarter valued at $33,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares in the company, valued at $99,987.30. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 204,322 shares of company stock valued at $9,939,221. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

BSX opened at $51.77 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a market cap of $75.02 billion, a price-to-earnings ratio of 20.96, a PEG ratio of 1.13 and a beta of 0.56. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The firm’s fifty day simple moving average is $46.06 and its two-hundred day simple moving average is $59.35.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: An investment analysis argues that Boston Scientific could recover from its recent headwinds, supporting the view that the company’s diversified portfolio and structural-growth markets can reaccelerate over time. Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
• Positive Sentiment: Analyst consensus remains broadly favorable, with brokerage recommendations suggesting that BSX may merit portfolio consideration. However, the article cautions that sell-side ratings can be overly optimistic and should not be used as the sole investment signal. Brokers Suggest Investing in Boston Scientific
• Neutral Sentiment: Recent fund commentary highlights Boston Scientific’s second-quarter performance and the factors that affected the stock, giving investors additional context on the company’s operating challenges but offering no new company guidance or specific catalyst. Here’s What Hurt Boston Scientific Corporation in Q2
• Negative Sentiment: Parnassus Investments identified a growth slowdown in key Boston Scientific businesses. That raises concerns about near-term revenue momentum and could pressure the stock if weaker growth persists, despite the company’s recent earnings beat and positive longer-term outlook. Boston Scientific Faces Growth Slowdown in Key Businesses

Analysts Set New Price Targets

A number of research analysts have weighed in on BSX shares. The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a research report on Thursday, May 28th. Truist Financial dropped their target price on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Royal Bank Of Canada cut their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, July 30th. Zacks Research cut Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Finally, Canaccord Genuity Group lowered their price target on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.